Fudan University
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 300
- Registration Number
- NCT02506842
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Cancer Institute & Hospital, Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center,Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Effect of Sufentanil and Ropivacaine
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT02488291
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 321
- Registration Number
- NCT02459457
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 55
- Registration Number
- NCT02415829
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 438
- Registration Number
- NCT02395640
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT02384811
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Cancer hospital Fudan University, Shanghai, Shanghai, China
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT02376452
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1
- Registration Number
- NCT02348281
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 150
- Registration Number
- NCT02341911
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 212
- Registration Number
- NCT02336750
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China